Lapatinib plus transtuzumab for HER-2 positiva metastatic breast cancer: Experience of use

• Egile Nagusiak: C. García-Muñoz (Egilea), S. Cortijo-Cascajares (Egilea), I. Cañamares-Orbis (Egilea), M. P. Goyache-Goñi (Egilea), J. M. Ferrari-Piquero (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2014-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract: Objective: To describe the outcomes produced by concomitant use of HER2-receptor inhibitors Lapatinib and Trastuzumab for the treatment of HER 2-positive metastatic breast cancer. Method: Retrospective observational study. Patients treated with Trastuzumab and Lapatinib between January of...